Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Qiagen N.V.    QGEN   NL0012169213

QIAGEN N.V.

(QGEN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryAll NewsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

QIAGEN : Reports Full Results for Second Quarter and First Half Of 2020

share with twitter share with LinkedIn share with facebook
08/04/2020 | 04:15pm EDT

  • Q2 2020 results:
  • Net sales of $443.3 million (+16% actual, +19% CER)
  • Diluted EPS $0.38; adjusted EPS $0.55 ($0.56 CER, +70% CER)
  • H1 2020 results:
  • Net sales of $815.3 million (+12% actual, +14% CER)
  • Diluted EPS $0.56; adjusted EPS $0.89 ($0.90 CER, +50% CER)
  • QIAGEN Boards have reaffirmed unanimous recommendation that QIAGEN shareholders accept Thermo Fisher Offer and tender their shares on or before August 10

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced full results of operations for the second quarter and first half of 2020, with net sales and adjusted earnings per share (EPS) in line with the preliminary results announced on July 9, 2020, and July 13, 2020. Net sales for the second quarter of 2020 grew 16% over the second quarter of 2019 (+19% at constant exchange rates, or CER), and adjusted earnings per share were $0.56 CER (+70% CER) for the quarter.

“The unprecedented demand for products used in coronavirus testing is driving QIAGEN’s performance in 2020. Our employees around the world are fully mobilized to serve all of our customers in the public health response to the pandemic throughout the world,” said Thierry Bernard, Chief Executive Officer of QIAGEN N.V. “Sales of testing solutions for the novel coronavirus were strong across all regions in the first half of 2020, for research in the Life Sciences and among Molecular Diagnostics customers for use in identifying patients with COVID-19. Demand for QuantiFERON-TB and other applications was reduced as the pandemic continues to curtail demand for non-COVID-19 healthcare and research activity.”

Mr. Bernard continued: “We recently reached an amended business combination agreement with Thermo Fisher Scientific Inc., increasing the tender offer price for QIAGEN shares to €43.00. QIAGEN’s Supervisory Board and Managing Board reaffirmed their unanimous support for the offer and their unanimous recommendation that QIAGEN shareholders accept and tender all of their QIAGEN shares in the offer prior to the end of the acceptance period, which has been extended to August 10, 2020. We look forward to working closely with Thermo Fisher to successfully complete this transaction.”

Roland Sackers, Chief Financial Officer of QIAGEN N.V., added: “QIAGEN’s swift response in scaling up production capacity for testing solutions to help fight the pandemic supported the double-digit sales growth in the second quarter. The coronavirus pandemic also had an impact on our business environment, reducing operating costs such as marketing and travel, and therefore resulting in an improvement of adjusted operating income margin and free cash flow.”

Please find the full press release pdf here


© Business Wire 2020
share with twitter share with LinkedIn share with facebook
All news about QIAGEN N.V.
09/18QIAGEN NV : Warburg Research reiterates its Neutral rating
MD
09/17QIAGEN N : fully acquires NeuMoDx Molecular, Inc., rounding out portfolio of PCR..
BU
09/15QIAGEN NV : DZ Bank reiterates its Neutral rating
MD
09/14QIAGEN N.V. : Notification and public disclosure of transactions by persons
EQ
09/14QIAGEN N.V. : Notification and public disclosure of transactions by persons
EQ
09/14QIAGEN N.V. : Notification and public disclosure of transactions by persons
EQ
09/11QIAGEN NV : Deutsche Bank remains its Buy rating
MD
09/09QIAGEN NV : Kepler Cheuvreux reiterates its Neutral rating
MD
09/08QIAGEN : to Launch Rapid Portable Test That Can Analyze Over 30 Samples Per Hour..
BU
08/27QIAGEN N.V. : Notification and public disclosure of transactions by persons
EQ
More news
Financials (USD)
Sales 2020 1 799 M - -
Net income 2020 331 M - -
Net Debt 2020 991 M - -
P/E ratio 2020 36,8x
Yield 2020 -
Capitalization 11 783 M 11 783 M -
EV / Sales 2020 7,10x
EV / Sales 2021 6,12x
Nbr of Employees 5 200
Free-Float 92,9%
Chart QIAGEN N.V.
Duration : Period :
Qiagen N.V. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends QIAGEN N.V.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 13
Average target price 56,00 $
Last Close Price 51,51 $
Spread / Highest target 28,1%
Spread / Average Target 8,72%
Spread / Lowest Target -26,2%
EPS Revisions
Managers
NameTitle
Thierry Bernard Chief Executive Officer
Lawrence A. Rosen Chairman-Supervisory Board
Barthold Piening Senior Vice President & Head-Global Operations
Roland Sackers Chief Financial Officer & Managing Director
Metin Colpan Independent Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
QIAGEN N.V.53.61%11 876
LONZA GROUP AG61.04%45 471
SEATTLE GENETICS, INC.61.87%32 181
CELLTRION, INC.40.88%29 371
IQVIA HOLDINGS INC.-2.08%28 939
MODERNA, INC.255.16%27 412